Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer
暂无分享,去创建一个
P. Boelle | C. Chomienne | M. Toubert | B. Cassinat | A. Cras | D. Darsin-Bettinger | N. Balitrand | Béatrice Politis
[1] R. di Lauro,et al. Intronic elements in the Na+/I- symporter gene (NIS) interact with retinoic acid receptors and mediate initiation of transcription , 2010, Nucleic acids research.
[2] G. Brent,et al. Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. , 2009, Cancer research.
[3] J. Romijn,et al. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma , 2008, Clinical endocrinology.
[4] C. Chomienne,et al. Epigenetic patterns of the retinoic acid receptor β2 promoter in retinoic acid-resistant thyroid cancer cells , 2007, Oncogene.
[5] P. Leung,et al. Involvement of NF‐κB subunit p65 and retinoic acid receptors, RARα and RXRα, in transcriptional regulation of the human GnRH II gene , 2007, The FEBS journal.
[6] E. Dmitrovsky,et al. A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.
[7] L. Hofbauer,et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells , 2007, Molecular and Cellular Endocrinology.
[8] W. V. Berghe,et al. Cross-talk between nuclear receptors and nuclear factor κB , 2006, Oncogene.
[9] J. Crowley,et al. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[11] S. Asa,et al. Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.
[12] J. Romijn,et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. , 2006, European journal of endocrinology.
[13] W. Lamph,et al. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours , 2006, British Journal of Cancer.
[14] R. Lotan,et al. N-(4-Hydroxyphenyl)Retinamide Inhibits Invasion, Suppresses Osteoclastogenesis, and Potentiates Apoptosis through Down-regulation of IκBα Kinase and Nuclear Factor-κB–Regulated Gene Products , 2005 .
[15] Chao Ma,et al. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[17] A. Leonardi,et al. Oncogenic and Anti-apoptotic Activity of NF-κB in Human Thyroid Carcinomas* , 2004, Journal of Biological Chemistry.
[18] G. Cook,et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).
[19] R. Niles. Signaling pathways in retinoid chemoprevention and treatment of cancer. , 2004, Mutation research.
[20] A. Sugawara,et al. Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. , 2004, The Journal of clinical endocrinology and metabolism.
[21] Ming-Tsan Lin,et al. Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-κB-dependent XIAP Up-Regulation* , 2004, Journal of Biological Chemistry.
[22] J. Köhrle,et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. , 2004, European journal of endocrinology.
[23] E. Winer,et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Lupu,et al. Cyr61 promotes breast tumorigenesis and cancer progression , 2002, Oncogene.
[25] D. Weidner,et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] H. Müller-Gärtner,et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[27] M. Duvic,et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Richmond,et al. Nuclear Factor-κB Activation by the CXC Chemokine Melanoma Growth-stimulatory Activity/Growth-regulated Protein Involves the MEKK1/p38 Mitogen-activated Protein Kinase Pathway* , 2001, The Journal of Biological Chemistry.
[29] R. Lauro,et al. Pax8 has a key role in thyroid cell differentiation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. Köhrle,et al. Retinoic acid redifferentiation therapy for thyroid cancer. , 2000, Thyroid : official journal of the American Thyroid Association.
[31] S. Filetti,et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. , 1999, European journal of endocrinology.
[32] P. Chambon,et al. Physical and Functional Interactions between Cellular Retinoic Acid Binding Protein II and the Retinoic Acid-Dependent Nuclear Complex , 1999, Molecular and Cellular Biology.
[33] V. Lazar,et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. , 1999, The Journal of clinical endocrinology and metabolism.
[34] C. Daumas-Duport,et al. Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. , 1999, Anticancer research.
[35] B. Haugen,et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. , 1999, The New England journal of medicine.
[36] G. Trinchieri,et al. Retinoids Inhibit Interleukin-12 Production in Macrophages through Physical Associations of Retinoid X Receptor and NFκB* , 1999, The Journal of Biological Chemistry.
[37] R. Fimmers,et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] P. Rochaix,et al. Reduced expression of retinoic acid receptor beta protein (RARβ) in human papillary thyroid carcinoma: immunohistochemical and Western blot study , 1998, Histopathology.
[39] C. Reiners,et al. Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma , 1998, World Journal of Surgery.
[40] J. Köhrle,et al. Functional retinoid and thyroid hormone receptors in human thyroid‐carcinoma cell lines and tissues , 1998, International journal of cancer.
[41] J. Köhrle,et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. , 1997, Biochemical and biophysical research communications.
[42] M. P. Miano,et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression , 1997, Oncogene.
[43] H. de Thé,et al. All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. , 1991, The Journal of clinical investigation.
[44] Tae Yong Kim,et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. , 2009, Endocrine journal.
[45] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[46] M. Karin. Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.
[47] G. Haegeman,et al. Cross-talk between nuclear receptors and nuclear factor kappaB. , 2006, Oncogene.
[48] R. Lotan,et al. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. , 2005, Cancer research.
[49] A. Leonardi,et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. , 2004, The Journal of biological chemistry.
[50] B. Haugen,et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. , 2004, The Journal of clinical endocrinology and metabolism.
[51] D. Wang,et al. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. , 2001, The Journal of biological chemistry.
[52] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[53] G. D. Vita,et al. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[54] A. Frilling,et al. Growth regulation of normal thyroids and thyroid tumors in man. , 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.